Certican Tabletten ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
67多発性嚢胞腎2

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-001485-16-AT
(EUCTR)
15/12/200616/11/2006A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDA multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD polycystic kidney disease
MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease
Product Name: Certican Tabletten
Product Code: RAD001
INN or Proposed INN: Everolimus
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
300France;Austria;Germany
2EUCTR2006-001485-16-DE
(EUCTR)
25/10/200619/01/2007A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDA multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD polycystic kidney disease
MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease
Product Name: Certican Tabletten
Product Code: RAD001
INN or Proposed INN: Everolimus
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
300France;Austria;Germany